These novel findings indicate the critical function of ERK1/2 and p38 activity in CS-related bladder cancer development and provide a plausible strategy for the search of potential interventional target of CS-associated bladder oncogenesis. The gene discussed is MAPK3; the disease is urinary bladder carcinoma.